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Introduction {#jgh312209-sec-0005}
============

Hepatocellular carcinoma (HCC) is the third leading cause of cancer‐related death worldwide and is thus an important health concern.[1](#jgh312209-bib-0001){ref-type="ref"} Despite oncological advances, the prognosis of patients with advanced HCC has remained poor,[2](#jgh312209-bib-0002){ref-type="ref"}, [3](#jgh312209-bib-0003){ref-type="ref"}, [4](#jgh312209-bib-0004){ref-type="ref"} partly because of the limited therapeutic options available for this malignancy. The optimal treatment strategy for HCC is a multimodal approach that includes multikinase inhibitors. Sorafenib is the first multikinase inhibitor approved for advanced HCC, and its capability to prolong overall survival (OS) and time to progression in patients with advanced HCC was first reported by the SHARP trial.[5](#jgh312209-bib-0005){ref-type="ref"} Until recently, the available systemic treatments for patients with advanced HCC were limited to sorafenib because various clinical trials failed to show any significant efficacy of novel systemic treatments for patients with advanced HCC or noninferiority of novel systemic treatments to the current standard therapy of sorafenib.[6](#jgh312209-bib-0006){ref-type="ref"}, [7](#jgh312209-bib-0007){ref-type="ref"}, [8](#jgh312209-bib-0008){ref-type="ref"} Recently, regorafenib, a multikinase inhibitor, was approved as second‐line systemic therapy for patients with advanced HCC who failed sorafenib therapy.[9](#jgh312209-bib-0009){ref-type="ref"} Lenvatinib, a novel multikinase inhibitor, has also been recently approved as a first‐line systematic therapy for patients with advanced HCC. The phase 3 clinical trial REFLECT[10](#jgh312209-bib-0010){ref-type="ref"} was the first to show that the OS of patients with advanced HCC who were treated with lenvatinib is noninferior to that of patients treated with sorafenib. In addition, the progression‐free survival of patients treated with lenvatinib was significantly longer than that of patients treated with sorafenib. However, in the REFLECT trial, patients who were treated with another multikinase inhibitor (sorafenib and/or regorafenib), had an HCC occupying ≥50% of the liver, had obvious invasion of the bile duct, demonstrated invasion at the main portal vein, had a Child‐Pugh grade B, and had hemoglobin \<8.5 g/dL or platelet count \<75 × 10^9^/L were excluded. Thus, the safety and efficacy of lenvatinib for such patients are not clarified. In addition, real‐world data are also limited.

Therefore, this study aimed to evaluate the early therapeutic response to lenvatinib in patients with nonresectable HCC in the real‐world setting, focusing on patients who did not meet the inclusion criteria of the REFLECT trial but did not have a contraindication according to the package insert of lenvatinib (Lenvima Capsules, Eisai Co., Ltd., Tokyo, Japan).

Methods {#jgh312209-sec-0006}
=======

*Patients* {#jgh312209-sec-0007}
----------

This was a retrospective multicenter study that enrolled patients who were given lenvatinib for advanced HCC between April and October 2018. The inclusion criteria were: (i) meeting the diagnostic criteria for advanced HCC according to the American Association for the Study of Liver Diseases guidelines,[11](#jgh312209-bib-0011){ref-type="ref"} (ii) follow up for more than 2 months after treatment initiation, (iii) treatment response was evaluated via dynamic computed tomography (CT) at baseline and 2 months after treatment initiation, and (iv) having adequate clinical data. Meanwhile, patients were excluded if they (i) had decompensated liver cirrhosis, (ii) were followed up less than 2 months, (iii) were treated with drugs listed in the contraindications for coadministration in the package insert of lenvatinib, and (iv) were not evaluated for treatment response at 2 months after treatment initiation.

We collected data on gender, age, etiology, blood cell count, alpha‐fetoprotein (AFP), des‐gamma‐carboxyprothrombin, the number of hepatic lesions and their maximum diameter, Child‐Pugh score, albumin‐bilirubin (ALBI) grade, and Barcelona Clinic Liver Cancer (BCLC) stage at baseline. Patients were assessed using laboratory tests and physical findings minimally at 2, 4, 6, and 8 weeks after treatment initiation to evaluate treatment response and safety. In addition, the efficacy and safety of lenvatinib for advanced HCC was evaluated among patients who did and did not meet the REFLECT trial inclusion criteria.

This study conformed to the ethical guidelines of the Declaration of Helsinki and was approved by the ethics committees of Hokkaido University Hospital (approval no. 017‐0521) and participating institutions. Informed consent was obtained from all patients.

*Treatment protocol* {#jgh312209-sec-0008}
--------------------

Lenvatinib (Lenvima) was administered orally for advanced HCC. The lenvatinib dose depended on the patients' weight: those who weighed \<60 kg were administered 8 mg of lenvatinib once daily, while those who weighed ≥60 kg were initially administered 12 mg of lenvatinib once daily. However, patients with Child‐Pugh grade B were initially treated with 8 mg of lenvatinib once daily regardless of weight.

Lenvatinib was discontinued when unacceptable adverse events (AEs) or disease progression was observed. In addition, the lenvatinib dose was adjusted, or treatment was interrupted, if the patients developed grade ≥3 or unacceptable AEs until the symptom resolved, as indicated on the package insert. AEs were evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.

*Evaluation of treatment response* {#jgh312209-sec-0009}
----------------------------------

Dynamic CT was performed at baseline and 8 weeks after treatment initiation to evaluate treatment response. The responses were classified by the attending physician according to the modified Response Evaluation Criteria in Solid Tumors.[12](#jgh312209-bib-0012){ref-type="ref"} Complete response was defined as the disappearance of all evidence of disease. Partial response was defined as a decrease of at least 30% in the sum of the longest diameters of the target lesions without the appearance of any new lesions. Progressive disease was defined as an increase of at least 20% in the sum of the longest diameters of the target lesions in the liver or the appearance of new lesions. Stable disease was defined as not meeting the criteria for complete response, partial response, or progressive disease. The efficacy of lenvatinib was further evaluated among patients who did and did not meet the REFLECT trial inclusion criteria.

*Statistical analysis* {#jgh312209-sec-0010}
----------------------

Continuous variables were analyzed using the paired Mann--Whitney *U* test, while categorical variables were analyzed using the chi‐square test and Fisher\'s exact test. Statistical analyses were performed using SPSS Statistics 22.0 (IBM Corp., Armonk, NY, USA), and *P* \< 0.05 was considered statistically significant.

Results {#jgh312209-sec-0011}
=======

*Patient characteristics* {#jgh312209-sec-0012}
-------------------------

Between April 2018 and October 2018, a total of 81 patients were started on lenvatinib for advanced HCC. Of these, 40 patients were excluded because they were followed up for less than 2 months (*n* = 12) or did not undergo CT examination at 2 months after treatment initiation (*n* = 28). In the 28 patients who did not undergo CT examination at 2 months after treatment initiation, 3 patients who discontinued lenvatinib within 2 weeks due to AEs and 1 patient who died within 2 months were included. Thus, 41 patients were enrolled in this study (Fig. [1](#jgh312209-fig-0001){ref-type="fig"}). The baseline patient characteristics are shown in Table [1](#jgh312209-tbl-0001){ref-type="table"}. The median patient age was 71 years (range, 46--97 years), and 37 (90.2%) patients were men. Fourteen patients were infected with hepatitis B virus, and seven patients were infected with the hepatitis C virus. The others had non‐B, non‐C etiology (*n* = 20). The most common Child‐Pugh score was 5 (*n* = 22), followed by a score of 6 (*n* = 14). Meanwhile, five patients had a Child‐Pugh score of more than 6. A majority of patients had ALBI grade 2 (*n* = 29, 70.7%) and BCLC stage C (*n* = 27, 65.9%. Ten patients had extrahepatic metastases. The median serum AFP level was 15.4 IU/mL (range, 1.6--449 909.0 IU/mL). There were 23 (56.1%) patients who did not meet the REFLECT inclusion criteria (history of tyrosine kinase inhibitor \[TKI\], *n* = 16; Child‐Pugh score B, *n* = 5; reduced platelet count, *n* = 2; bile duct invasion, *n* = 4; and performance status score 2, *n* = 1). These patients had a significantly higher AFP level (*P* = 0.044) and a higher Child‐Pugh score (*P* = 0.0165) (Table [1](#jgh312209-tbl-0001){ref-type="table"}).

![Study flowchart. CR, complete response; CT, computed tomography; HCC, hepatocellular carcinoma; PD, progressive disease; PR, partial response; SD, stable disease.](JGH3-4-54-g001){#jgh312209-fig-0001}

###### 

Baseline patient characteristics

  Clinical characteristics                Overall cohort (*n* = 41)   Met the REFLECT criteria (*n* = 18)   Did not meet the REFLECT criteria (*n* = 23)   *P* value
  -------------------------------------- --------------------------- ------------------------------------- ---------------------------------------------- -----------
  Age (years)                                    71 (46--97)                      75 (46--83)                               70 (54--97)                     0.1026
  Gender                                                                                                                                                    0.0259
  Male                                               37                               18                                         19                       
  Female                                              4                                0                                         4                        
  Etiology                                                                                                                                                  0.0311
  HBV                                                14                                3                                         11                       
  HCV                                                 7                                2                                         5                        
  Others                                             20                               13                                         7                        
  ECOG PS                                                                                                                                                   0.3003
  0                                                  28                               11                                         17                       
  1                                                  12                                7                                         5                        
  2                                                   1                                0                                         1                        
  BMI (kg/m^2^)                               23.9 (13.5--33.4)                24.4 (13.5--29.7)                         22.7 (17.4--33.4)                  0.4863
  White blood cell (/mm^3)^                   4600 (2000--9900)                4500 (2900--9100)                         4700 (2000--9900)                  0.8954
  Neutrophil (/mm^3^)                         2645 (1360--5788)                2663 (1705--5788)                         2501 (1360--5379)                  0.6303
  Neutrophil/lymphocyte ratio                 2.79 (0.85--9.00)                2.41 (0.97--9.00)                         3.62 (0.85--5.23)                  0.2752
  Platelet (×10^4^/μL)                        13.8 (4.4--33.6)                 14.7 (8.5--25.8)                           13.6 (4.4--33.6)                  0.6176
  Prothrombin time (%)                       94.0 (46.6--150.0)               98.5 (74.3--150.0)                         88.3 (46.6--116.9)                 0.0978
  NH3 (μg/dL)                                   41 (13--118)                      35 (18--76)                               43 (13--118)                    0.1565
  Albumin (g/dL)                               3.7 (2.8--4.5)                   3.8 (3.0--4.5)                             3.5 (2.8--4.3)                   0.0615
  Total bilirubin (mg/dL)                      0.7 (0.2--3.1)                   0.7 (0.2--2.1)                             0.7 (0.3--3.1)                   0.6535
  ALBI grade                                                                                                                                                0.6135
  1                                                  12                                6                                         6                        
  2                                                  29                               12                                         17                       
  AST (IU/L)                                    37 (19--181)                      32 (23--93)                               38 (19--118)                    0.5281
  ALT (IU/L)                                     23 (13--96)                      24 (13--96)                               23 (13--96)                     0.9266
  Child‐Pugh score                                                                                                                                          0.0165
  5                                                  22                               13                                         9                        
  6                                                  14                                5                                         9                        
  7--9                                                5                                0                                         5                        
  AFP (ng/mL)                               15.4 (1.6--449 909.0)             5.8 (2.0--19 394.3)                      52.3 (1.6--449 909.0)                0.0444
  DCP (mAU/mL)                                734 (12--43 200)                  384 (15043200)                           1409 (13--27 425)                  0.1458
  Maximum intrahepatic tumor size (mm)           37 (8--135)                     41 (10--123)                               36 (8--135)                     0.6254
  Number of intrahepatic tumors                                                                                                                             0.4371
  None                                                3                                6                                         1                        
  1                                                  11                               10                                         5                        
  Multiple                                           27                                2                                         17                       
  TNM stage                                                                                                                                                 0.8603
  II                                                  3                                2                                         1                        
  III                                                17                                7                                         10                       
  IVA                                                11                                5                                         6                        
  VIB                                                10                                4                                         6                        
  BCLC stage                                                                                                                                              
  B                                                  14                                6                                         8                        
  C                                                  27                               12                                         15                         0.9226
  Met the Milan criteria                          2 (4.9%)                         1 (5.6%)                                   1 (4.3%)                      0.8591
  Positive for Vp                                10 (24.4%)                        4 (22.2%)                                 6 (26.1%)                      0.8532
  Vp2                                                 4                                2                                         2                        
  Vp3                                                 6                                2                                         4                        
  Vp4                                                 0                                0                                         0                        
  Positive for Vv                                 2 (4.9%)                         2 (11.1%)                                   0 (0%)                       0.0642
  Positive for bile duct invasion                 4 (9.8%)                          0 (0%)                                   4 (17.4%)                      0.0259
  Positive for LN metastasis                      5 (12.2%)                        2 (11.1%)                                 3 (13.0%)                      0.8507
  Positive for EHM                               10 (24.4%)                        4 (22.2%)                                 6 (26.1%)                      0.7743
  Naïve: recurrence                                 7:36                             3:15                                       2:21                        0.1500
  History of hypertension                        25 (61.0%)                       10 (55.6%)                                 15 (65.2%)                     0.5294
  History of hepatectomy                         16 (39.0%)                        6 (33.3%)                                 10 (43.5%)                     0.5074
  History of RFA                                 11 (26.8%)                        5 (27.8%)                                 6 (26.1%)                      0.9036
  History of TACE                                30 (73.2%)                       13 (72.2%)                                 17 (73.9%)                     0.9036
  History of sorafenib                           16 (39.0%)                         0 (0%)                                   16 (69.6%)                    \<0.0001
  History of regorafenib                          4 (9.8%)                          0 (0%)                                   4 (17.4%)                      0.0259

Data are presented as median (range) or in *n*.

AFP, alpha‐fetoprotein; ALBI grade, albumin‐bilirubin grade; ALT, alanine aminotransferase; AST, aspartate transaminase; BCLC, the Barcelona Clinic Liver Cancer; BMI, body mass index; DCP, des‐gamma‐carboxy prothrombin; ECOG PS, Eastern Cooperative Oncology Group performance status; EHM, extra‐hepatic metastasis; HBV, hepatitis B virus; HCV, hepatitis C virus; LN, lymph node; RFA, radiofrequency ablation; TACE, transcatheter arterial chemoembolization; TNM, tumor node metastasis stage of the Liver Cancer Study Group of Japan; Vp, portal vein invasion; Vv, hepatic vein invasion.

*Treatment response* {#jgh312209-sec-0013}
--------------------

Treatment response at 8 weeks after treatment initiation was evaluated in all patients. Of the 41 patients, 5 (12.2%), 20 (48.8%), 12 (29.3%), and 4 (9.3%) showed complete response, partial response, stable disease, and progressive disease, respectively (Table [2](#jgh312209-tbl-0002){ref-type="table"}). The objective response rate (i.e. the total rate of patients with complete response and partial response) was 61.2%. The disease control rate (i.e. the total rate of patients with complete response, partial response, and stable disease) was 90.2%. Among the patients who did not meet the REFLECT inclusion criteria, the objective response rate was 56.3% (9/16), 60% (3/5), and 100% (4/4) in those with a history of TKI administration, Child‐Pugh score B, and bile duct invasion, respectively.

###### 

Clinical response to lenvatinib

  Response                        Overall cohort (*n* = 41)   Met the REFLECT criteria (*n* = 18)   Did not meet the REFLECT criteria (*n* = 23)   *P* value
  ------------------------------ --------------------------- ------------------------------------- ---------------------------------------------- -----------
  Complete response, *n* (%)              5 (12.2)                         2 (11.1)                                   3 (13.0)                    
  Partial response, *n* (%)               20 (48.8)                        9 (50.0)                                  11 (47.8)                    
  Stable disease, *n* (%)                 12 (29.3)                        5 (27.8)                                   7 (30.4)                    
  Progressive disease, *n* (%)             4 (9.8)                         2 (11.1)                                   2 (8.7)                     
  Objective response rate               61.0% (25/41)                    61.1% (11/18)                             60.9% (14/23)                    0.8293
  Disease control rate                  90.2% (37/41)                    88.9% (16/18)                             91.3% (21/23)                    0.7965

The objective response rate (*P* = 0.8293) and disease control rate (*P* = 0.7965) were similar between patients who did and did not meet the REFLECT inclusion criteria. Moreover, the tumor reduction ratio (Fig. [2](#jgh312209-fig-0002){ref-type="fig"}) and rate of AFP change were also similar between the two patient groups (*P* = 0.8849 and *P* = 0.7743).

![Waterfall plot of changes in targeted tumor size as assessed according to mRECIST in the (a) overall patient cohort; (b) patients who meet the REFLECT inclusion criteria and (c) patients who did not meet the REFLECT inclusion criteria.](JGH3-4-54-g002){#jgh312209-fig-0002}

*Safety and treatment discontinuation due to AEs* {#jgh312209-sec-0014}
-------------------------------------------------

The safety profile of lenvatinib as assessed between patients who did and did not meet the REFLECT inclusion criteria is summarized in Table [3](#jgh312209-tbl-0003){ref-type="table"}. Overall, the most common AEs of any grade were hand‐foot syndrome (*n* = 23, 56.1%), general fatigue (*n* = 24, 58.5%), loss of appetite (*n* = 28, 68.3%), hypertension (*n* = 28, 68.3%), and increased urinary albumin (*n* = 23, 56.1%). Meanwhile, the most common grade \>3 AEs were hand‐foot syndrome (*n* = 6, 14.6%), hypertension (*n* = 5, 12.2%), and decreased platelet count (*n* = 5, 12.2%). The rate of grade \>3 AEs was similar between patients who did and did not meet the REFLECT inclusion criteria**.**

###### 

Adverse events and treatment discontinuations

                                        Overall cohort (*n* = 41)   Met the REFLECT criteria (*n* = 18)   Did not meet the REFLECT criteria (*n* = 23)   *P* value
  ------------------------------------ --------------------------- ------------------------------------- ---------------------------------------------- -----------
  Treatment discontinuation                     3 (7.3%)                         1 (5.6%)                                   2 (8.7%)                      0.6982
  Interruption and/or dose reduction           30 (73.2%)                       15 (83.3%)                                 15 (65.2%)                      0.186
  Worsened Child Pugh score                    18 (43.4%)                        8 (44.4%)                                 10 (43.5%)                     0.9507

  Adverse events              Any grade    Grade \> 3   Any grade    Grade \> 3   Any grade    Grade \> 3
  -------------------------- ------------ ------------ ------------ ------------ ------------ ------------
  HFS                         23 (56.1%)   6 (14.6%)    12 (66.7%)   3 (16.7%)    11 (47.8%)   3 (13.0%)
  General fatigue             24 (58.5%)     0 (0%)     13 (72.2%)     0 (0%)     11 (47.8%)     0 (0%)
  Appetite loss               28 (68.3%)    1 (2.4%)    14 (77.8%)    1 (5.6%)    14 (60.9%)     0 (0%)
  Diarrhea                    9 (22.0%)     1 (2.4%)    3 (16.7%)     1 (5.6%)    6 (26.1%)      0 (0%)
  Hypertension                28 (68.3%)   5 (12.2%)    15 (83.3%)   2 (11.1%)    13 (56.5%)   3 (13.3%)
  Hepatic coma                 3 (7.3%)     3 (7.3%)     1 (5.6%)     1 (5.6%)     2 (8.7%)     2 (8.7%)
  Weight loss                 6 (14.6%)      0 (0%)     5 (27.8%)      0 (0%)      1 (4.3%)      0 (0%)
  Proteinuria                 23 (56.1%)    1 (2.4%)    11 (61.1%)    1 (5.6%)    12 (52.2%)     0 (0%)
  Decreased platelet count    21 (51.2%)   5 (12.2%)    10 (55.6%)   2 (11.1%)    11 (47.8%)   3 (13.0%)
  Fever                        1 (2.4%)      0 (0%)       0 (0%)       0 (0%)      1 (4.3%)      0 (0%)
  Hypothyroidism              21 (51.2%)     0 (0%)     11 (61.1%)     0 (0%)     10 (43.5%)     0 (0%)
  Dysgeusia                    3 (7.3%)      0 (0%)      1 (5.6%)      0 (0%)      2 (8.7%)      0 (0%)
  Rash                         1 (2.4%)     1 (2.4%)     1 (5.6%)     1 (5.6%)      0 (0%)       0 (0%)
  Decreased albumin           21 (51.2%)     0 (0%)     9 (50.0%)      0 (0%)     12 (52.2%)     0 (0%)
  Increased bilirubin         8 (19.5%)     1 (2.4%)    4 (22.2%)     1 (5.6%)    4 (17.4%)     1 (4.3%)
  Ascites                     5 (12.2%)      0 (0%)      1 (5.6%)      0 (0%)     4 (17.4%)      0 (0%)
  Hyperthyroidism              1 (2.4%)      0 (0%)      1 (5.6%)      0 (0%)       0 (0%)       0 (0%)
  Stomatitis                   1 (2.4%)      0 (0%)      1 (5.6%)      0 (0%)       0 (0%)       0 (0%)
  Increased creatinine         4 (9.8%)      0 (0%)     2 (11.1%)      0 (0%)      2 (8.7%)      0 (0%)

Data are presented as *n* (%).

HFS, hand‐foot syndrome.

Overall, three patients (7.3%) discontinued treatment due to drug‐related AEs (hyperbilirubinemia, *n* = 1; hepatic encephalopathy, *n* = 2). In addition, treatment was interrupted or the dose was reduced in 30 patients (73.2%). The rate of treatment discontinuation and treatment interruption and/or dose reduction was similar between patients who did and did not meet the REFLECT inclusion criteria.

Next, we evaluated the changes in Child‐Pugh score between baseline and at 8 weeks after lenvatinib initiation. Eighteen patients (43.4%) had a worsened Child‐Pugh score (Table [3](#jgh312209-tbl-0003){ref-type="table"}). The rate of worsened Child‐Pugh score was similar between patients who did and did not meet the REFLECT inclusion criteria. However, the rate of worsened Child‐Pugh score was significantly higher among patients with a Child‐Pugh score of ≥6 (*n* = 19) than that of patients with a Child‐Pugh score of 5 (*n* = 22) (12/19 (63.2%) *vs* 6/22 (27.3%), *P* = 0.019).

Discussion {#jgh312209-sec-0015}
==========

In this real‐world retrospective multicenter study of lenvatinib for patients with advanced HCC, more than 50% of the included patients did not meet the REFLECT trial inclusion criteria. Overall, the early response and tolerability were favorable and were similar between patients who did and did not meet the REFLECT trial inclusion trial. Thus, lenvatinib might be safe and effective even for patients who did not meet the REFLECT inclusion criteria.

The multikinase inhibitor sorafenib has only been approved as first‐line systemic therapy for patients with advanced HCC for almost 10 years. Although the recently concluded phase 3 trial REFLECT showed the noninferiority of OS in lenvatinib compared with that in sorafenib for patients with advanced HCC,[10](#jgh312209-bib-0010){ref-type="ref"} the trial excluded patients with bile duct invasion, Child‐Pugh grade B, and reduced platelet or hemoglobin count. Thus, the efficacy and safety of lenvatinib for these patients have not been clarified. In the current real‐world study, more than 50% of patients started on lenvatinib did not meet the REFLECT trial inclusion trial. This helped to clarify the efficacy and safety of lenvatinib for these patients.

Lenvatinib is an orally active TKI targeting VEGFR1--3, FGFR1--4, PDGFR‐α, c‐Kit, and RET.[13](#jgh312209-bib-0013){ref-type="ref"}, [14](#jgh312209-bib-0014){ref-type="ref"} Thus, compared with sorafenib, lenvatinib could inhibit several additional cell signalings, including fibroblast growth factor (FGF) signaling. Recently, in vitro and in vivo analyses demonstrated that acquired resistance to sorafenib posttreatment is mediated by the activation of FGF signaling.[15](#jgh312209-bib-0015){ref-type="ref"}, [16](#jgh312209-bib-0016){ref-type="ref"} Thus, lenvatinib might be effective for patients who previously failed to respond to sorafenib because lenvatinib could inhibit FGF signaling. Similar to the results of the current study, the study by Hiraoka *et al*.[17](#jgh312209-bib-0017){ref-type="ref"} also showed favorable treatment outcomes of lenvatinib for patients who had a history of TKI, supporting the results of the in vitro and vivo analyses. However, these findings still need to be validated in further studies with large a sample size.

In this study, the objective response rate was better than that of the REFLECT trial. Notably, a subgroup analysis of Japanese patients in the REFLECT study[18](#jgh312209-bib-0018){ref-type="ref"} showed a higher objective response rate, thus indicating that race might affect the treatment outcomes of lenvatinib. A total of 78% (32/41) of patients in the current study had a baseline AFP level of \<200 ng/mL. It is reported that baseline AFP level affected the prognosis and treatment outcomes[10](#jgh312209-bib-0010){ref-type="ref"} of patients treated with systemic chemotherapy for HCC.[19](#jgh312209-bib-0019){ref-type="ref"} In addition, the number of patients with extrahepatic metastasis, which predicts poor response,[10](#jgh312209-bib-0010){ref-type="ref"} was lower than that of the REFLECT trial. Thus, the high number of patients with lower baseline AFP level and small number of patients with extrahepatic metastasis in the current study might have affected the favorable outcomes obtained. In addition, the limited number of included patients might have also affected the treatment outcome.

In this study, we analyzed the early response to and safety of lenvatinib for patients with advanced HCC at 8 weeks after treatment initiation. Therefore, the results could not show the patients' prognosis. However, Lencioni *et al*. recently reported that objective response and OS were significantly correlated in systemic therapy for patients with advanced HCC.[20](#jgh312209-bib-0020){ref-type="ref"} The objective response rate of lenvatinib in this study seemed to be favorable compared with previously reported outcomes on sorafenib.[5](#jgh312209-bib-0005){ref-type="ref"} Thus, the favorable efficacy of lenvatinib for patients who did not meet the REFLECT criteria might predict favorable prognosis. In addition, Kudo *et al*.[18](#jgh312209-bib-0018){ref-type="ref"} also reported that this favorable response rate might motivate patients, resulting in higher compliance.

Three patients (7.3%) discontinued lenvatinib due to drug‐related AEs, and treatment was interrupted or the dose was reduced in 30 patients (73.2%). However, as shown in Table [3](#jgh312209-tbl-0003){ref-type="table"}, the occurrence rate of these events was similar between patients who did and did not meet the REFLECT inclusion criteria. This finding indicates that lenvatinib is safe and tolerable even in patients who did not meet the REFLECT inclusion criteria.

The most common any‐grade AEs were similar between the current study and those in REFLECT and included hand‐foot syndrome, general fatigue, appetite loss, and hypertension. Most AEs were controllable. However, two patients discontinued lenvatinib due to hepatic encephalopathy. Both patients had esophageal varices at baseline. Thus, patients with portal hypertension at baseline should be monitored closely for hepatic encephalopathy during treatment.

Overall, 43.4% (18/41) of patients had a worsened Child‐Pugh score (Table [3](#jgh312209-tbl-0003){ref-type="table"}). The occurrence rate of worsened Child‐Pugh score was similar between patients who did and did not meet the REFLECT inclusion criteria. However, the rate of worsened Child‐Pugh score was significantly higher in patients with a baseline Child‐Pugh score of ≥6 than those with a score of 5 (63.2*vs* 27.3%, *P* = 0.019). Because the prognosis of patients with HCC is significantly affected by hepatic function,[21](#jgh312209-bib-0021){ref-type="ref"} lenvatinib therapy yields more benefit when initiated, while hepatic function is still preserved.

This study has several limitations that must be considered when interpreting the results. First, the study was retrospective in design; included a limited number of patients; and had several missing data, including PT‐INR and MELD scores. The observation period was also short and limited to only 8 weeks. Moreover, we included three patients who discontinued lenvatinib within 2 weeks due to AEs and one patient who died within 2 months in the group of 28 excluded patients who did not undergo CT examination at 2 months after treatment initiations. In addition, the patients who did not meet the REFLECT inclusion trial were heterogeneous. Therefore, prospective studies with larger cohorts and longer observation periods are needed to validate our findings.

In conclusion, this real‐world study showed that lenvatinib yields a high early response rate and tolerability for advanced HCC in both patients who did and did not meet the REFLECT trial inclusion criteria.
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